News Agency
Men's Weekly

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

  • Written by PR Newswire
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
  • ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years.
  • ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and are a known driver of...

Read more: Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to...

Commercial Scaffolding Services and the Backbone of Large-Scale Projects

Large construction projects rely on more than concrete and steel to rise safely and efficiently. Commercial scaffolding services form the temporary framework that allows complex work to happen at height, supporting trades, materials, and workflows across multi-level sites. From early... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion